Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4803088 | 1.00 | KEAP1 (0.38) | KEAP1NFE2L2SLC7A5CYP1A2CYP2D6 | |
| SCHEMBL17912379 | 1.00 | KEAP1 (0.38) | KEAP1NFE2L2SLC7A5CYP1A2CYP2D6 | |
| SCHEMBL29481029 | 1.00 | KEAP1 (0.38) | KEAP1NFE2L2SLC7A5CYP1A2CYP2D6 | |
| SCHEMBL3594424 | 0.82 | MEN1 (0.36) | KEAP1NFE2L2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1326634 | 0.79 | SMPD2 (0.41) | — | |
| SCHEMBL7229620 | 0.79 | SMPD2 (0.41) | — | |
| SCHEMBL1432658 | 0.79 | SMPD2 (0.41) | — | |
| SCHEMBL642839 | 0.79 | SMN1; SMN2 (0.41) | SLC7A5CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL9382586 | 0.79 | SMN1; SMN2 (0.41) | SLC7A5CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4797996 | 0.78 | PTPN1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425550-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2008-09-16 | — | — | US | disclosed |
| US-7098235-B2 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | SHER PHILIP | 2006-06-15 | — | — | US | disclosed |
| US-7057046-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | PYGL, PNLIP, PYGM | KEAP1 1348/4885NFE2L2 3145/4885SLC7A5 2309/4885 |
| US-20040002495-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS2 | KEAP1 1167/4885NFE2L2 3364/4885SLC7A5 2284/4885 |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS1 | KEAP1 1316/4885NFE2L2 3777/4885SLC7A5 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.